Targeting therapeutic gene expression to human prostate cancers

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Most current therapies against human carcinoma of the prostate are palliative rather than curative. Thus, there is a pressing need for new therapies directed against this common tumor, based on knowledge of the basic biology of the prostate, rather than by extrapolation of treatments from other tumor types. This review presents the various levels of prostate targeting which could be and have been applied, at the attachment, expression and therapeutic gene levels to eliminate prostate carcinoma cells in extraprostatic sires. To achieve optimal and safe targeting, a combination approach will be necessary, as there are few genes whose expression call provide absolute prostate specificity.

Original languageEnglish
Pages (from-to)389-399
Number of pages11
JournalCurrent opinion in molecular therapeutics
Volume2
Issue number4
Publication statusPublished - Aug 2000

Keywords

  • gene targeting
  • prostatic cancer
  • specificity
  • ANDROGEN-REGULATED EXPRESSION
  • RECOMBINANT ADENOVIRUS VECTOR
  • MEMBRANE ANTIGEN EXPRESSION
  • GROWTH-FACTOR RECEPTORS
  • MONOCLONAL-ANTIBODY
  • CARCINOMA-CELLS
  • IN-VIVO
  • INTRAEPITHELIAL NEOPLASIA
  • CLINICAL-TRIAL
  • STEROID 5-ALPHA-REDUCTASE

Cite this